Gated drug delivery systems

Last updated
Illustration of a gated drug delivery platform. The cargo is retained in the scaffolding the by the gatekeeper. In the right conditions, the gatekeeper will detach from the scaffolding and the cargo can be released. Gated Delivery System.png
Illustration of a gated drug delivery platform. The cargo is retained in the scaffolding the by the gatekeeper. In the right conditions, the gatekeeper will detach from the scaffolding and the cargo can be released.

Gated drug delivery systems are a method of controlled drug release that center around the use of physical molecules that cover the pores of drug carriers until triggered for removal by an external stimulus. Gated drug delivery systems are a recent innovation in the field of drug delivery and pose as a promising candidate for future drug delivery systems that are effective at targeting certain sites without having leakages or off target effects in normal tissues. This new technology has the potential to be used in a variety of tissues over a wide range of disease states and has the added benefit of protecting healthy tissues and reducing systemic side effects. [1]

Contents

Uses

Gated drug delivery systems are an emerging concept that have drawn a lot of attention for their wide variety of potential applications in the medical field. The abnormal physiological conditions found within the tumor environment provide a breadth of options that could be used for externally stimulating these systems to release cargo. Gated systems in cancer therapy also have the added effect of reducing off target effects and decreasing leakage and delivery of drug to normal tissues. Another use for this technology could also be antibacterial regulation. These systems could be used to limit bacterial resistance as well as accumulation of antibiotics within the body. Antibacterial regulation potentially opens the door to using gated systems in theranostics, in which the system is able to detect an issue and then provide a therapeutic response. [2]

There is also the potential for inhalable pulmonary drug delivery. [3] With an increase in respiratory disease cases, the need for a drug delivery system that can be targeted to the lungs and provide sustained release is becoming more severe. This type of system would be applicable to patients experiencing asthma, pneumonia, obstructive pulmonary disease, and a number of other lung related diseases. [4]

History

The history of gated drug delivery systems starts in the mid-1960s when the concept of zero order controlled drug delivery was first thought of. Researchers raced to be able to find a drug delivery platform that would be able to have perfectly sustained drug release. These efforts were initially on the macroscopic level with some of the first controlled drug delivery (CDD) devices being an ophthalmic insert, an intrauterine device, and a skin patch. [5] In the 1970s the drug delivery field shifted from macroscopic systems and started to delve into microscopic systems. Ideas such as steroid loaded poly (lactic-co-glycolic acid), PLGA, microparticles came into existence. The next major jump came in the 1980s in the form of nanotherapeutics. There were some major technological advances that allowed this next generation of drug delivery systems to come along. Those ideas were PEGylation, active targeting, and the enhanced permeation and retention effect (EPR). [5]

Some of the issues that had been seen with earlier renditions of nanoparticle drug delivery was that there were off target effects from drug being delivered to normal tissue, the delivery system wasn't highly controllable, and there wasn't optimal accumulation of drug in the targeted area. [6] This is when the development of "smart drug delivery" originated. Encapsulated within the idea of smart drug delivery is the use of gated delivery systems. Researchers discovered that certain materials could be loaded and capped to prevent premature drug release. The caps could subsequently be removed using different external stimuli. This created a class of drug delivery systems that were able to solve a number of problems exhibited by normal nanoparticle drug delivery systems. These smart drug delivery systems are able to deliver the drug with minimal leakage, can be actively or passively targeted to different areas within the body, and will only release drug in the presence of certain triggers, creating a sustained local response and accumulation of drug at the disease area. [6]

Scaffold fabrication

There are many different materials and fabrication methods that can be used to produce gated drug delivery scaffolding. In general, porous materials, such as mesoporous silica nanoparticles are used because of their expansive surface area, large loading capacity, and porous structures. [2] These characteristics make it possible to load a variety of molecules that vary greatly in size.

Mesoporous silica nanoparticles

Mesoporous silica nanoparticles (MSN) are considered to be one of the most widely used systems for drug delivery. MSN's have some of the characteristic features of gated systems such as being porous and having a high loading capacity, but they also exhibit some special features such as increased biocompatibility and chemical inertness. [7] These delivery systems are composed of two parts: the inorganic scaffold and the molecular gates. In a study conducted by the Kong Lab at Deakin University in Australia, the researchers generated MSN's by adding tetraethyl orthosilicate to aqueous cetyltrimethylammonium bromide. [8] The MSN's they created had a surface area of 363 m^2/g, an average pore size of 2.59 nm, and a pore volume of 0.33 cm^3/g. [8]

Mesoporous carbon Nanoparticles

Mesoporous carbon nanoparticles (MCN) are similar to MSN's. They have a similar structure and share key physical properties and characteristics. However, it has been found that MCN's can exhibit lower toxicity that MSN's. To date, not much research has been done on MCN's. The Du lab based in Nanjing, China took made MSN templates using the common method of combining CTAB and TEOS. The researchers then took the MSN templates and dispersed them in a glucose solution followed by autoclaving the mixture to produce a reaction. The product was then subjected to carbonization at 900 degrees Celsius and the MCN's were generated. [9] The researchers found that MCN's had a surface area of 1575 m^2/g, a pore size of 2.2 nm, and an average diameter of 115 nm. [9]

External stimuli

There is a number of external triggers that can be used to release cargo on gated delivery systems. Examples of some triggers include pH, redox, enzyme, light, temperature, magnetic, ultrasound, and small molecule responsive gated systems.

pH

Illustration of a pH triggered gated delivery system. The cargo is retained within the scaffolding when the platform is in non-acidic conditions. When the platform reached the acidic tumor environment, the bonds between the scaffolding and the gatekeeper are hydrolyzed and the cargo is released. PH gated drug delivery.png
Illustration of a pH triggered gated delivery system. The cargo is retained within the scaffolding when the platform is in non-acidic conditions. When the platform reached the acidic tumor environment, the bonds between the scaffolding and the gatekeeper are hydrolyzed and the cargo is released.

One of the most common triggers for drug delivery systems is pH. This stimulus is abundantly used in cancer therapies due to the fact that the tumor microenvironment is acidic. The development of pH triggered systems meant that drug could be introduced to the body but not be deployed until encountering the tumor microenvironment. Hence a possible and probable reason that pH triggered systems are so common. There are a few approaches to making these systems. One method is using linkages that dissolve at certain pH levels. As the system enters an acidic environment, the linkages that hold that gates onto the porous scaffold are hydrolyzed and the cargo can be released. [7] Examples of pH linkages are imine, amides, esters, and acetals. [7] Another method that can be used is protonation. This method relies on electrostatic interactions between the gate molecule and the porous scaffold. The two will be linked together with a certain molecule, for example, acetylated carboxymethyl. When the system reaches an acidic environment, protonation of the molecule is initiated. The protonation causes a disruption in the linkage and the cargo can be released. [7]

Redox

Redox reactions are also used for gated delivery systems. Within cells and the bloodstream there are several reducing agents that can be used to trigger drug release in gated systems. The most common reducing agent used in gated delivery system is glutathione (GSH) because it has been determined that GSH is the most abundant reducing agent in the body. [1] GSH also has significantly different concentrations between the intracellular and extracellular environments making it easier to target either environment without getting triggered by the other. [1] Furthermore, GSH is found in higher concentration within tumor cells. [1] This provides another way to have sustained and local release of drug at tumor sites. There are generally 2 different mechanisms for this type of gated system. One method is to cleave disulfide bonds. Another method is to cleave bonds through the use of reactive oxygen species (ROS). Bonds that are able to be cleaved by ROS are generally thioketals, ketals, and diselenides. [7]

Enzyme

Enzyme responsive gated materials are another class of gated delivery systems. In these scenarios, enzymes can trigger release of the gates from the scaffolds in drug delivery systems. The mechanism for this type of gate is that certain linkages are used that can be hydrolyzed by select enzymes. The two most popular choices are protease and hyaluronidase. An advantage of using enzyme responsive triggers is that there is a large amount of substrate specificity, and the enzymes are able to trigger their target with high selectivity, even under mild conditions. [6] Another advantage of this system is that enzymes are found throughout the entire body and work on almost all biological processes so the delivery system could potentially be activated in any part of the body during many points within a singular process. [6] One study done by the Martinez-Manez lab in Valencia, Spain aimed to generate MSNs linked to poly-l-glutamic acid (PGA) gates through peptide bonds. The trigger for this system was the presence of a lysosomal proteolytic enzyme (protease), in this case, pronase. The researchers found that in the absence of pronase, the system was only able to release less than 20% of its cargo in 24 hours, however, in the presence of pronase, there was a 90% release of cargo within 5 hours. [10]

Magnetic and temperature

Within the topic of gated drug delivery systems, utilizing magnetic forces generally goes hand in hand with temperature stimulus. The phenomenon of magnetic hyperthermia is when superparamagnetic nanoparticles reorient themselves after being exposed to heat generated by an alternating magnetic field (AMF). This concept has been utilized within the drug delivery field wherein gatekeepers are magnetically linked to the scaffolding and upon the application of heat, reorient and allow for the release of drug. [7] This particular method has not been researched as heavily given the drawback that high energy is needed to produce the AMF and uncap the system. However, the Vallet-Regi lab based in Madrid, Spain decided to investigate the possibility of using magnetic gates bound to the scaffold using DNA. The lab generated oligonucleotide-modified superparamagnetic mesoporous silica nanoparticles. They capped the scaffolding using iron oxide nanoparticles that carried complementary DNA to the scaffold's oligonucleotide sequence. What the lab found was that they were able to cap their system due to the DNA coming together and creating a double strand. Upon heating the system using an AMF, the DNA bonds detached, the system became uncapped, and the drug was able to be released. [11] Furthermore, the lab found that this linkage was reversible. As temperature was reduced, the DNA was able to re-link to its complementary half. This study was able to illustrate the possibility of having a drug delivery system that could be remotely triggered and exhibit an on-off switch. [11]

Electrostatic

Researchers started investigating electrostatic gating because some trigger drug delivery systems on the market are not entirely feasible. The main complaint of these other systems is that continual external stimulation is required for the therapy to function. [12] In order to combat this complaint, the Grattoni lab in Houston, Texas started working on a drug delivery system that utilized electrostatic gating. The researchers generated a silicon carbide coated nanofluidic membrane that would have controlled release of a drug when a buried electrode was exposed to low intensity voltage. [12] What the researchers found was that their device was able to successfully release drug and do it in such a way that drug release was proportional to the applied voltage. They also found that the device was chemically inert, making it feasible for long term implantation. [12]

Related Research Articles

Nanomedicine is the medical application of nanotechnology. Nanomedicine ranges from the medical applications of nanomaterials and biological devices, to nanoelectronic biosensors, and even possible future applications of molecular nanotechnology such as biological machines. Current problems for nanomedicine involve understanding the issues related to toxicity and environmental impact of nanoscale materials.

<span class="mw-page-title-main">Mesoporous material</span>

A mesoporous material is a nanoporous material containing pores with diameters between 2 and 50 nm, according to IUPAC nomenclature. For comparison, IUPAC defines microporous material as a material having pores smaller than 2 nm in diameter and macroporous material as a material having pores larger than 50 nm in diameter.

<span class="mw-page-title-main">Nanochemistry</span> Combination of chemistry and nanoscience

Nanochemistry is an emerging sub-discipline of the chemical and material sciences that deals with the development of new methods for creating nanoscale materials. The term "nanochemistry" was first used by Ozin in 1992 as 'the uses of chemical synthesis to reproducibly afford nanomaterials from the atom "up", contrary to the nanoengineering and nanophysics approach that operates from the bulk "down"'. Nanochemistry focuses on solid-state chemistry that emphasizes synthesis of building blocks that are dependent on size, surface, shape, and defect properties, rather than the actual production of matter. Atomic and molecular properties mainly deal with the degrees of freedom of atoms in the periodic table. However, nanochemistry introduced other degrees of freedom that controls material's behaviors by transformation into solutions. Nanoscale objects exhibit novel material properties, largely as a consequence of their finite small size. Several chemical modifications on nanometer-scaled structures approve size dependent effects.

Targeted drug delivery, sometimes called smart drug delivery, is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. This means of delivery is largely founded on nanomedicine, which plans to employ nanoparticle-mediated drug delivery in order to combat the downfalls of conventional drug delivery. These nanoparticles would be loaded with drugs and targeted to specific parts of the body where there is solely diseased tissue, thereby avoiding interaction with healthy tissue. The goal of a targeted drug delivery system is to prolong, localize, target and have a protected drug interaction with the diseased tissue. The conventional drug delivery system is the absorption of the drug across a biological membrane, whereas the targeted release system releases the drug in a dosage form. The advantages to the targeted release system is the reduction in the frequency of the dosages taken by the patient, having a more uniform effect of the drug, reduction of drug side-effects, and reduced fluctuation in circulating drug levels. The disadvantage of the system is high cost, which makes productivity more difficult, and the reduced ability to adjust the dosages.

<span class="mw-page-title-main">Mesoporous silica</span> Nano-scale porous silica compound

Mesoporous silica is a form of silica that is characterised by its mesoporous structure, that is, having pores that range from 2 nm to 50 nm in diameter. According to IUPAC's terminology, mesoporosity sits between microporous (<2 nm) and macroporous (>50 nm). Mesoporous silica is a relatively recent development in nanotechnology. The most common types of mesoporous nanoparticles are MCM-41 and SBA-15. Research continues on the particles, which have applications in catalysis, drug delivery and imaging. Mesoporous ordered silica films have been also obtained with different pore topologies.

Polymer nanocomposites (PNC) consist of a polymer or copolymer having nanoparticles or nanofillers dispersed in the polymer matrix. These may be of different shape, but at least one dimension must be in the range of 1–50 nm. These PNC's belong to the category of multi-phase systems that consume nearly 95% of plastics production. These systems require controlled mixing/compounding, stabilization of the achieved dispersion, orientation of the dispersed phase, and the compounding strategies for all MPS, including PNC, are similar. Alternatively, polymer can be infiltrated into 1D, 2D, 3D preform creating high content polymer nanocomposites.

Magnetic nanoparticles (MNPs) are a class of nanoparticle that can be manipulated using magnetic fields. Such particles commonly consist of two components, a magnetic material, often iron, nickel and cobalt, and a chemical component that has functionality. While nanoparticles are smaller than 1 micrometer in diameter, the larger microbeads are 0.5–500 micrometer in diameter. Magnetic nanoparticle clusters that are composed of a number of individual magnetic nanoparticles are known as magnetic nanobeads with a diameter of 50–200 nanometers. Magnetic nanoparticle clusters are a basis for their further magnetic assembly into magnetic nanochains. The magnetic nanoparticles have been the focus of much research recently because they possess attractive properties which could see potential use in catalysis including nanomaterial-based catalysts, biomedicine and tissue specific targeting, magnetically tunable colloidal photonic crystals, microfluidics, magnetic resonance imaging, magnetic particle imaging, data storage, environmental remediation, nanofluids, optical filters, defect sensor, magnetic cooling and cation sensors.

A nanogel is a polymer-based, crosslinked hydrogel particle on the sub-micron scale. These complex networks of polymers present a unique opportunity in the field of drug delivery at the intersection of nanoparticles and hydrogel synthesis. Nanogels can be natural, synthetic, or a combination of the two and have a high degree of tunability in terms of their size, shape, surface functionalization, and degradation mechanisms. Given these inherent characteristics in addition to their biocompatibility and capacity to encapsulate small drugs and molecules, nanogels are a promising strategy to treat disease and dysfunction by serving as delivery vehicles capable of navigating across challenging physiological barriers within the body. 

Smart polymers, stimuli-responsive polymers or functional polymers are high-performance polymers that change according to the environment they are in.

A nanocapsule is a nanoscale shell made from a nontoxic polymer. They are vesicular systems made of a polymeric membrane which encapsulates an inner liquid core at the nanoscale. Nanocapsules have many uses, including promising medical applications for drug delivery, food enhancement, nutraceuticals, and for self-healing materials. The benefits of encapsulation methods are for protection of these substances to protect in the adverse environment, for controlled release, and for precision targeting. Nanocapsules can potentially be used as MRI-guided nanorobots or nanobots, although challenges remain.

Nanocomposite hydrogels are nanomaterial-filled, hydrated, polymeric networks that exhibit higher elasticity and strength relative to traditionally made hydrogels. A range of natural and synthetic polymers are used to design nanocomposite network. By controlling the interactions between nanoparticles and polymer chains, a range of physical, chemical, and biological properties can be engineered. The combination of organic (polymer) and inorganic (clay) structure gives these hydrogels improved physical, chemical, electrical, biological, and swelling/de-swelling properties that cannot be achieved by either material alone. Inspired by flexible biological tissues, researchers incorporate carbon-based, polymeric, ceramic and/or metallic nanomaterials to give these hydrogels superior characteristics like optical properties and stimulus-sensitivity which can potentially be very helpful to medical and mechanical fields.

Niveen M. Khashab is a Lebanese chemist and an associate Professor of chemical Sciences and engineering at King Abdullah University of Science and Technology in Saudi Arabia since 2009. She is a laureate of the 2017 L'Oréal-UNESCO Awards for Women in Science "for her contributions to innovative smart hybrid materials aimed at drug delivery and for developing new techniques to monitor intracellular antioxidant activity." She is also a fellow of the Royal Chemical Society, and a member of the American Chemical Society.

Jeffrey I. Zink is an American molecular biologist and chemist currently a Distinguished Professor at University of California, Los Angeles whose interests are in materials, nanoscience, physical and inorganic chemistry. His current research is examining molecules containing metal and nanomaterials. He worked with Fraser Stoddart to help develop machines that could be applied to deliver drugs. According to Google Scholar, his highest citations are 2,503, 2,131, 1,968, 1,873, and 1,150.

Ashok M. Raichur is an Indian materials scientist, nanotechnologist and a professor at the Department of Materials Engineering of the Indian Institute of Science, Bangalore. Known for his studies on the use of nanotechnology for biomedical and environmental applications, Raichur is a former Alexander von Humboldt Fellow and a life member of the National Academy of Sciences, India. The Department of Biotechnology of the Government of India awarded him the National Bioscience Award for Career Development, one of the highest Indian science awards, for his contributions to biosciences, in 2009.

Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.

Hamid Ghandehari is an Iranian-American drug delivery research scientist, and a professor in the Departments of Pharmaceutics and Pharmaceutical Chemistry and Biomedical Engineering at the University of Utah. His research is focused in recombinant polymers for drug and gene delivery, nanotoxicology of dendritic and inorganic constructs, water-soluble polymers for targeted delivery and poly(amidoamine) dendrimers for oral delivery.

<span class="mw-page-title-main">Dextran drug delivery systems</span> Polymeric drug carrier

Dextran drug delivery systems involve the use of the natural glucose polymer dextran in applications as a prodrug, nanoparticle, microsphere, micelle, and hydrogel drug carrier in the field of targeted and controlled drug delivery. According to several in vitro and animal research studies, dextran carriers reduce off-site toxicity and improve local drug concentration at the target tissue site. This technology has significant implications as a potential strategy for delivering therapeutics to treat cancer, cardiovascular diseases, pulmonary diseases, bone diseases, liver diseases, colonic diseases, infections, and HIV.

Conventional drug delivery is limited by the inability to control dosing, target specific sites, and achieve targeted permeability. Traditional methods of delivering therapeutics to the body experience challenges in achieving and maintaining maximum therapeutic effect while avoiding the effects of drug toxicity. Many drugs that are delivered orally or parenterally do not include mechanisms for sustained release, and as a result they require higher and more frequent dosing to achieve any therapeutic effect for the patient. As a result, the field of drug delivery systems developed into a large focus area for pharmaceutical research to address these limitations and improve quality of care for patients. Within the broad field of drug delivery, the development of stimuli-responsive drug delivery systems has created the ability to tune drug delivery systems to achieve more controlled dosing and targeted specificity based on material response to exogenous and endogenous stimuli.

Pullulan bioconjugates are systems that use pullulan as a scaffold to attach biological materials to, such as drugs. These systems can be used to enhance the delivery of drugs to specific environments or the mechanism of delivery. These systems can be used in order to deliver drugs in response to stimuli, create a more controlled and sustained release, and provide a more targeted delivery of certain drugs.

<span class="mw-page-title-main">Reduction-sensitive nanoparticles</span> Drug delivery method

Reduction-sensitive nanoparticles (RSNP) consist of nanocarriers that are chemically responsive to reduction. Drug delivery systems using RSNP can be loaded with different drugs that are designed to be released within a concentrated reducing environment, such as the tumor-targeted microenvironment. Reduction-Sensitive Nanoparticles provide an efficient method of targeted drug delivery for the improved controlled release of medication within localized areas of the body.

References

  1. 1 2 3 4 Wang, Ying; Han, Ning; Zhao, Qinfu; Bai, Ling; Li, Jia; Jiang, Tongying; Wang, Siling (May 2015). "Redox-responsive mesoporous silica as carriers for controlled drug delivery: A comparative study based on silica and PEG gatekeepers". European Journal of Pharmaceutical Sciences. 72: 12–20. doi:10.1016/j.ejps.2015.02.008. PMID   25701727.
  2. 1 2 Li, Zheng; Song, Nan; Yang, Ying-Wei (August 2019). "Stimuli-Responsive Drug-Delivery Systems Based on Supramolecular Nanovalves". Matter. 1 (2): 345–368. doi: 10.1016/j.matt.2019.05.019 . S2CID   201220688.
  3. ↑ Lee, Jinhyun Hannah; Yeo, Yoon (March 2015). "Controlled drug release from pharmaceutical nanocarriers". Chemical Engineering Science. 125: 75–84. doi:10.1016/j.ces.2014.08.046. PMC   4322773 . PMID   25684779.
  4. ↑ Thananukul, Kamonchanok; Kaewsaneha, Chariya; Opaprakasit, Pakorn; Lebaz, Noureddine; Errachid, Abdelhamid; Elaissari, Abdelhamid (July 2021). "Smart gating porous particles as new carriers for drug delivery". Advanced Drug Delivery Reviews. 174: 425–446. doi: 10.1016/j.addr.2021.04.023 . PMID   33930490. S2CID   233471925.
  5. 1 2 Hoffman, Allan S. (December 2008). "The origins and evolution of "controlled" drug delivery systems". Journal of Controlled Release. 132 (3): 153–163. doi:10.1016/j.jconrel.2008.08.012. PMID   18817820.
  6. 1 2 3 4 Liu, Dong; Yang, Fang; Xiong, Fei; Gu, Ning (2016). "The Smart Drug Delivery System and Its Clinical Potential". Theranostics. 6 (9): 1306–1323. doi:10.7150/thno.14858. ISSN   1838-7640. PMC   4924501 . PMID   27375781.
  7. 1 2 3 4 5 6 García‐Fernández, Alba; Aznar, Elena; Martínez‐Máñez, Ramón; Sancenón, Félix (January 2020). "New Advances in In Vivo Applications of Gated Mesoporous Silica as Drug Delivery Nanocarriers". Small. 16 (3): 1902242. doi:10.1002/smll.201902242. ISSN   1613-6810. PMID   31846230. S2CID   209389329.
  8. 1 2 Yi, Zhifeng; Hussain, Hashmath I.; Feng, Chunfang; Sun, Dequan; She, Fenghua; Rookes, James E.; Cahill, David M.; Kong, Lingxue (2015-05-13). "Functionalized Mesoporous Silica Nanoparticles with Redox-Responsive Short-Chain Gatekeepers for Agrochemical Delivery". ACS Applied Materials & Interfaces. 7 (18): 9937–9946. doi:10.1021/acsami.5b02131. ISSN   1944-8244. PMID   25902154.
  9. 1 2 Huang, Xuan; Wu, Shanshan; Du, Xuezhong (May 2016). "Gated mesoporous carbon nanoparticles as drug delivery system for stimuli-responsive controlled release". Carbon. 101: 135–142. doi:10.1016/j.carbon.2016.01.094.
  10. ↑ Tukappa, Asha; Ultimo, Amelia; de la Torre, Cristina; Pardo, Teresa; Sancenón, Félix; Martínez-Máñez, Ramón (2016-08-23). "Polyglutamic Acid-Gated Mesoporous Silica Nanoparticles for Enzyme-Controlled Drug Delivery". Langmuir. 32 (33): 8507–8515. doi:10.1021/acs.langmuir.6b01715. hdl: 10251/86458 . ISSN   0743-7463. PMID   27468799.
  11. 1 2 Ruiz-Hernández, Eduardo; Baeza, Alejandro; Vallet-Regí, María (2011-02-22). "Smart Drug Delivery through DNA/Magnetic Nanoparticle Gates". ACS Nano. 5 (2): 1259–1266. doi:10.1021/nn1029229. ISSN   1936-0851. PMID   21250653.
  12. 1 2 3 Di Trani, Nicola; Silvestri, Antonia; Sizovs, Antons; Wang, Yu; Erm, Donald R.; Demarchi, Danilo; Liu, Xuewu; Grattoni, Alessandro (2020). "Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery". Lab on a Chip. 20 (9): 1562–1576. doi:10.1039/D0LC00121J. ISSN   1473-0197. PMC   7249613 . PMID   32249279.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.